Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion type Assertion NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_head.
- NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion description "[This phase II study assesses the impact of second-line weekly irinotecan (CPT-11)/docetaxel in non-small cell lung cancer (NSCLC) patients, and gauges the uridine diphosphate glucuronosyl transferase (UGT1A1) polymorphism influence in toxicity and antitumor activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_provenance.
- NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion evidence source_evidence_literature NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_provenance.
- NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion SIO_000772 14586211 NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_provenance.
- NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion wasDerivedFrom befree-20150227 NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_provenance.
- NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_assertion wasGeneratedBy ECO_0000203 NP925828.RADuFU5LtWwiwsnxXZniUP5TsVnxY8Jb3uvRLgqLby6-U130_provenance.